C. Eaton

发表

iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.

Ishtiaq Rehman, Simon S Cross, Freddie C Hamdy, 2008, Journal of proteome research.

Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment.

R. Coleman, C. Eaton, Robert E. Coleman, 2003, Cancer treatment reviews.

Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo

I. Holen, P. Croucher, Ning Wang, 2014, Clinical Cancer Research.

Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL‐Induced Apoptosis

F. Hamdy, I. Holen, N. Cross, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone-directed therapy in prostate cancer: Rationale and novel approaches

F. Hamdy, C. Eaton, K. Linton, 2016 .

Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non‐neoplastic prostate cell lines

K. Griffiths, D. Barrow, C. Eaton, 1997, The Prostate.

5 The role of endocrine therapy in prostatic cancer

K. Griffiths, C. Eaton, 1990 .

iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer

S. Cross, F. Hamdy, P. Wright, 2012, PloS one.

The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer

I. Holen, P. Croucher, Ning Wang, 2015, Journal of experimental & clinical cancer research : CR.

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

F. Hamdy, I. Holen, P. Croucher, 2002, Cancer research.

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells

I. Holen, E. Waterman, N. Cross, 2008, Journal of cellular biochemistry.

Imaging the effects of castration on bone turnover and hormone‐independent prostate cancer colonization of bone

I. Holen, N. Cross, C. Eaton, 2008, The Prostate.

Parathyroid Hormone (PTH) Increases Skeletal Tumour Growth and Alters Tumour Distribution in an In Vivo Model of Breast Cancer

I. Holen, P. Croucher, N. Brown, 2018, International journal of molecular sciences.

The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells

M. Cecchini, C. Eaton, F. Ahmed, 2018, Biotechnology and applied biochemistry.

Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis

I. Holen, R. Coleman, N. Cross, 2004, Breast Cancer Research and Treatment.

Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases

M. Cecchini, P. Clézardin, F. Mege-Lechevallier, 2012, The Prostate.

Regulation of prostatic growth

C. Eaton, P. Davies, M. Phillips, 1988 .

Regulation of prostate growth.

C. Eaton, P. Davies, Peter Davies, 1991, The Journal of endocrinology.

Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer

F. Hamdy, A. Wetterwald, M. Cecchini, 2010, The Prostate.

Hormonal treatment of advanced disease: some newer aspects.

K. Griffiths, M. Harper, C. Eaton, 1994, Seminars in oncology.

The survival effect of prolactin on PC3 prostate cancer cells.

F. Hamdy, K. Al-Sakkaf, B. Brown, 2003, European urology.

Fibroblast Growth Factors and Their Receptors in Parathyroid Disease

B. J. Harrison, C. Eaton, D. Lambert, 1998, World Journal of Surgery.

Role of endogenous transforming growth factor β (TGFβ) 1 in prostatic stromal cells *

C. Chapple, C. Eaton, A. Bretland, 2001 .

Growth Factor Receptors and Oncogene Expression in Prostate Cells

C. Eaton, P. Davies, M. Elizabeth, 1988, American journal of clinical oncology.

Metastatic malignant disease of unknown origin.

P. Deckers, C. Eaton, E. Spatz, 1983, American journal of surgery.

Opposing actions of TGFβ1 and FGF2 on growth, differentiation and extracellular matrix accumulation in prostatic stromal cells

A. Harvey, N. Cross, C. Eaton, 2006, Growth factors.

Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: Isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1

C. Eaton, C. G. Pierrepoint, C. Eaton, 1988, The Prostate.

Prostate cancer cells home to bone using a novel in vivo model: Modulation by the integrin antagonist GLPG0187

F. Hamdy, N. Brown, M. Cecchini, 2015, International journal of cancer.

Growth factor involvement and oncogene expression in prostatic tumours.

C. Eaton, P. Davies, M. Phillips, 1988, Journal of steroid biochemistry.

Bone marrow stromal cells promote growth and survival of prostate cancer cells.

M. Papageorgiou, N. Cross, C. Eaton, 2007, Biochemical Society transactions.

Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?

S. Cross, I. Holen, S. Balasubramanian, 2005, Breast Cancer Research and Treatment.

Mitotic quiescence, but not unique “stemness,” marks the phenotype of bone metastasis‐initiating cells in prostate cancer

I. Holen, P. Croucher, Ning Wang, 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor‐α and the expression of various growth factors in neoplastic and non‐neoplastic prostatic cell lines

K. Griffiths, D. Barrow, J. Gee, 1997, The Prostate.

Some Aspects of the Molecular Endocrinology of Prostatic Cancer

K. Griffiths, M. Harper, C. Eaton, 1996 .

Aetiology and pathogenesis of benign prostatic hyperplasia

C. Eaton, 2003, Current opinion in urology.

High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer.

F. Hamdy, M. Cecchini, G. Thalmann, 2010, Cancer research.

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche

A. Zannettino, T. Phan, J. Pettitt, 2015, Nature Communications.

Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer

S. Cross, F. Hamdy, S. Winder, 2013, Scientific Reports.

Prostate Cancer Cells Preferentially Home to Osteoblast‐rich Areas in the Early Stages of Bone Metastasis: Evidence From In Vivo Models

I. Holen, P. Croucher, Ning Wang, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target

Jian Luo, A. Gartland, Ning Wang, 2020, Cells.

Eight‐plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study

S. Cross, F. Hamdy, P. Wright, 2010, The Prostate.

EZH2 promotes proliferation and invasiveness of prostate cancer cells

F. Hamdy, R. Bryant, N. Cross, 2007, The Prostate.

Steroids and the prostate

K. Griffiths, M. Harper, C. Eaton, 1991, The Journal of Steroid Biochemistry and Molecular Biology.

Studies of androgen and estrogen binding in normal canine prostatic tissue and in epithelial and stromal cell lines derived from the canine prostate

C. Eaton, C. G. Pierrepoint, T. Hamilton, 1985 .

Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.

I. Holen, P. Croucher, Ning Wang, 2014, Endocrine-related cancer.

Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate

C. Eaton, P. Davies, 1989, The Prostate.

Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.

I. Ellis, R. Blamey, R. Nicholson, 1993, European journal of cancer.

Dystroglycan function is a novel determinant of tumor growth and behavior in prostate cancer

S. Cross, F. Hamdy, S. Winder, 2013, The Prostate.

Prostate cancer proteomics: The urgent need for clinically validated biomarkers

F. Hamdy, P. Wright, J. Catto, 2009, Proteomics. Clinical applications.

Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo

I. Holen, C. Eaton, F. Nutter, 2016, Clinical & Experimental Metastasis.

OPG‐Fc inhibits ovariectomy‐induced growth of disseminated breast cancer cells in bone

I. Holen, P. Croucher, Ning Wang, 2015, International journal of cancer.

Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFβ)

H. Klingler, C. Eaton, A. Bretland, 1999, The Prostate.

Steroid hormones and the pathogenesis of benign prostatic hyperplasia.

K. Griffiths, M. Harper, C. Eaton, 1991, European urology.

Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo

I. Holen, C. Evans, C. Eaton, 2015, Clinical & Experimental Metastasis.

Pure antioestrogens in breast cancer - experimental and clinical observations

A. Howell, M. Dowsett, R. Mansel, 1994 .

Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression

C. Dumontet, M. Cecchini, P. Clézardin, 2013, The Prostate.

Expression of β‐dystroglycan is reduced or absent in many human carcinomas

S. Cross, F. Hamdy, S. Winder, 2008, Histopathology.

The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer

I. Holen, P. Croucher, Ning Wang, 2015, Journal of experimental & clinical cancer research : CR.

The expression and regulation of ADAMTS‐1, ‐4, ‐5, ‐9, and ‐15, and TIMP‐3 by TGFβ1 in prostate cells: relevance to the accumulation of versican

F. Hamdy, N. Cross, C. Eaton, 2005, The Prostate.

Abstract PD07-08: Zoledronic acid specifically inhibits development of bone metastases in the post-menopausal setting – evidence from an in vivo breast cancer model

I. Holen, P. Croucher, Ning Wang, 2012 .

Prostate cancer cells home to bone using a novel in vivo model : modulation by the integrin antagonist GLPG 0187 Running title : new in vivo model for tracking early prostate cancer homing to bone

Nicola J Brown, F. Hamdy, N. Brown, 2014 .

Cancer of the prostate: endocrine factors.

K. Griffiths, M. Harper, C. Eaton, 1987, Oxford reviews of reproductive biology.

Effect of n‐6 polyunsaturated fatty acids on growth and lipid composition of neoplastic and non‐neoplastic canine prostate epithelial cell cultures

A. Stobart, C. Eaton, H. E. Jones, 1997, The Prostate.

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer

F. Hamdy, I. Holen, P. Croucher, 2004, The Prostate.

Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells

P. Croucher, C. Eaton, M. Lawson, 2019, Bone.

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers

F. Hamdy, I. Holen, E. Waterman, 2007, International journal of cancer.

Endocrine Aspects of Prostate Cancer

K. Griffiths, M. Harper, C. Eaton, 1994 .